Expert Opinion on Investigational Drugs

[1]  K. Pandya,et al.  Active specific immunotherapy for metastatic colorectal carcinoma: phase I study of an allogeneic cell vaccine plus low-dose interleukin-1 alpha. , 1999, Journal of immunotherapy.

[2]  W. Scheithauer,et al.  Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Hanna,et al.  Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial , 1999, The Lancet.

[4]  B. Reigner,et al.  A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  E. Van Cutsem,et al.  A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  C. Tournigand,et al.  Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Fukushima,et al.  Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil , 1998, Anti-cancer drugs.

[8]  D. Kerr,et al.  Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  B. Reigner,et al.  Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Ychou,et al.  Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Pazdur.  Irinotecan: toward clinical end points in drug development. , 1998, Oncology.

[12]  R. Pazdur,et al.  UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. , 1998, Anti-cancer drugs.

[13]  H. Ishitsuka,et al.  Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. , 1998, European journal of cancer.

[14]  B. Reigner,et al.  Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Boddy,et al.  Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Vasey,et al.  A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  C. Tournigand,et al.  Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. , 1997, European journal of cancer.

[18]  J. Uchida,et al.  Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats , 1996, Cancer Chemotherapy and Pharmacology.

[19]  D. Kerr,et al.  Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  M. Fukushima,et al.  Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. , 1996, Anti-cancer drugs.

[21]  D. V. Von Hoff,et al.  Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  T. Chou,et al.  Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Kerr,et al.  'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group. , 1995, European journal of cancer.

[24]  G. Riethmüller,et al.  Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma , 1994, The Lancet.

[25]  A. Mazard,et al.  Kinetics of the reaction of cis-platinum compounds with DNA in vitro. , 1985, Biochemical and biophysical research communications.

[26]  E. Van Cutsem,et al.  Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). , 1999, European journal of cancer.

[27]  G. Blackledge.  New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex'). , 1998, British Journal of Cancer.

[28]  A. Calvert,et al.  Clinical studies with MTA. , 1998, British Journal of Cancer.

[29]  S. Culine,et al.  Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Ychou,et al.  Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.